Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Delayed Nasdaq
Other stock markets
 03:57:20 2024-04-18 pm EDT 		5-day change 1st Jan Change
393.1 USD +0.00% Intraday chart for Vertex Pharmaceuticals Incorporated -1.83% -3.44%
04:21pm Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain MT
Apr. 17 UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating MT

Evolution of the average Target Price on Vertex Pharmaceuticals Incorporated

Price target over the last 5 years

History of analyst recommendation changes

9819576742283bd4a45515ff.tyLJ4wZnUO_HMvvSQi4UHP2O5O1-4wn5jiutVg3bOQ0.5Ei4q0kDIoWjYq2wOwNXK5nNioU_lT_B6mGaEVKdc3ffd6WBRT0ql5deww~c52d45e51dd6cb67d877a109a8acdf77

Analyst Recommendations on Vertex Pharmaceuticals Incorporated

UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating MT
Guggenheim Adjusts Vertex Pharmaceuticals' Price Target to $450 From $445 MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT
HC Wainwright Raises Vertex Pharmaceuticals' Price Target to $462 From $457, Maintains Buy Rating MT
Wedbush Downgrades Alpine Immune Sciences to Neutral From Outperform, Raises Price Target to $65 From $47, Expects Vertex Deal to Close MT
Evercore ISI Upgrades Vertex Pharmaceuticals to Outperform From In Line MT
RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal MT
RBC Trims Price Target on Vertex Pharmaceuticals to $417 From $420, Keeps Sector Perform Rating MT
Wolfe Research Initiates Vertex Pharmaceuticals With Outperform Rating, $515 Price Target MT
Fed officials fail to convince investors, who are focused on earnings Our Logo
ANALYST RECOMMENDATIONS : Caterpillar, Eli Lilly, Intel, Meta, T-Mobile... Our Logo
Stifel Adjusts Vertex Pharmaceuticals' Price Target to $430 From $373, Keeps Hold Rating MT
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $511 From $485, Keeps Outperform Rating MT
Goldman Sachs Adjusts Vertex Pharmaceuticals' Price Target to $578 From $559, Keeps Buy Rating MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $540 From $500, Maintains Overweight Rating MT
UBS Adjusts Price Target on Vertex Pharmaceuticals to $498 From $513, Maintains Buy Rating MT
Evercore ISI Downgrades Vertex Pharmaceuticals to In Line From Outperform, Adjusts Price Target to $438 From $436 MT
JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $450 From $438, Keeps Overweight Rating MT
Barclays Adjusts Price Target on Vertex Pharmaceuticals to $472 From $446, Keeps Overweight Rating MT
Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $440 From $400, Keeps Hold Rating MT
HC Wainwright Adjusts Price Target on Vertex Pharmaceuticals to $457 From $397, Keeps Buy Rating MT
RBC Lifts PT on Vertex Pharmaceuticals to $420 From $397 After 'Solid' Q4 2023 Results, 'Favorable' Guidance, 'Positive' Vanza Data; Sector Perform Kept MT
Job data is good for the economy, not for rate cuts Our Logo
Bernstein Downgrades Vertex Pharmaceuticals to Market Perform From Outperform, $450 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
393.1 USD
Average target price
460.3 USD
Spread / Average Target
+17.11%
High Price Target
574 USD
Spread / Highest target
+46.02%
Low Price Target
325 USD
Spread / Lowest Target
-17.32%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Vertex Pharmaceuticals Incorporated

UBS
Guggenheim
HC Wainwright
Evercore ISI
RBC Capital Markets
Wolfe Research
Leerink Partners
Goldman Sachs
Stifel Nicolaus
Wells Fargo Securities
JPMorgan Chase
Barclays
Jefferies & Co.
Bernstein
Maxim
Oppenheimer
BofA Securities
Cantor Fitzgerald
Canaccord Genuity
Morgan Stanley
BMO Capital
TD Cowen
Piper Sandler
Truist Securities
Baird
SVB Securities LLC
Argus
Cowen
SVB Leerink
Raymond James
Citigroup
Daiwa Securities
Credit Suisse

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VRTX Stock
  4. Consensus Vertex Pharmaceuticals Incorporated